ME02847B - Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala - Google Patents
Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanalaInfo
- Publication number
- ME02847B ME02847B MEP-2017-235A MEP23517A ME02847B ME 02847 B ME02847 B ME 02847B ME P23517 A MEP23517 A ME P23517A ME 02847 B ME02847 B ME 02847B
- Authority
- ME
- Montenegro
- Prior art keywords
- alkyl
- heteroaryl
- independently selected
- halo
- cycloalkyl
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- -1 -O-CHF2 Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 150000002431 hydrogen Chemical group 0.000 claims 6
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000004419 alkynylene group Chemical group 0.000 claims 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 229910007161 Si(CH3)3 Inorganic materials 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 208000008253 Systolic Heart Failure Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (1)
1. Jednjenje sa formulom III:gde:R1 je aril ili heteroaril odabran iz grupe koja se sastoji od:gde pomenuti aril ili heteroaril su supstituisani sa jednim dva, ili tri supstituenta nezavisno odabranih iz grupe koja se sastoji od hidroksi!, halo, -NO2, CN, -SF5, -Si(CH3)3 -O-CF3, -O-R20, -S-R20, -C(O)-R20, C(O)OH,-N(R20)(R22), -C(O)-N(R20)(R22), -N(R20)-C(O)-R22,-N(R20)-S(=O)2-R26, -S(=O)2- R20, -S(=O)2-N(R20)(R22), C1-C3 alkoksi, C1-4 alkil, C2-4 alkenil, C2-4 alkinil, cikloalkil, heteroaril, i heterociklil;gde pomenuti alkoksi, alkil, alkenil, alkinil, heteroaril, cikloalkil, ili heterociklil su po izboru supstituisani sa jednim, dva, ili tri supstituenta nezavisno odabranih od hidroksil, halo, -NO2 , -O-CF3, -O-CHF2, fenil, heterociklil, heteroaril, cikloalkil, -N(R 20)(R22), -C(O)-R20, -C(O)-O-R20, -C(O)-N(R20)(R22), -CN, i -O-R20,ili gde R1 je supstituisan sa jednim, dva, ili tri supstituenta nezavisno odabranih odR2 je nezavisno odabran iz grupe koja se sastoji od vodonika, po izboru supstituisanog alkila, amino, po izboru supstituisanog alkoksi, -CF3, -O-CF3, -CN, i -N(R 20)C(O)-R22 ;R3 je nezavisno odabran iz grupe koja se sastoji od vodonika, alkila,- CF3, -halo, i -O-R4 je nezavisno odabran iz grupe koja se sastoji od vodonika, hidroksila, halo, C1-4 alkila, C1-C3 alkoksi, -R25-N(R20)(R22), -R25-O-R20, -R25-C(O)-O-R20, -R25-C(O)-N(R20)(R22),-R25-C(O)-O-N(R20)(R22), -R25-N(R20)-C(O)-R22, i -R25-O-C(O)-N(R20)(R22),gde pomenuti alkil su po izboru supstituisani sa jednim, dva, ili tri supstituenta nezavisno odabranih od hidroksil i halo,Q je odabran od kovalentne veze ili C2-4 alkinilena;Ra je vodonik, C1-15 alkil, C1-4 alkoksi, -C(O)-O-R26, -C(O)-N(R26)(R28), -N(R20)-S(=O)2-R20, cikloalkil, aril, heteroaril, i heterociklil, gde pomenuti alkil je po izboru supstituisan sa jedan, dva, ili tri supstituenta nezavisno odabranih od hidroksil, halo, -NO2, -O-CF3, -O-CHF2, cikloalkil, -CN, i C1-4 alkoksi; ipomenuti alkoksi, cikloalkil, aril, heterociklil, ili heteroaril su po izboru supstituisani sa jednim, dva, ili tri supstituenta nezavisno odabranih od hidroksila, halo, -NO2, -O-CF3, -O-CHF2, fenila, heterociklila, heteroarila, cikloalkila, -N(R20)(R22), -C(O)-R20, -C(O)-O-R20, -C(O)-N(R20)(R22), -CN, i -O-R20; iliRa je-Y-Z-R25-R23-R2o, gde,Y je kovalentna veza ili odabran od C1-C3 alkilena po izboru supstituisanog sa jedan ili dva C1-C3 alkila ili fluora grupe;Z je C2-4 alkinilen, -O-, -S-, -NR", -NR"-, -NR5'-C(O), -NR"-C(O)-NR5'- ili -C(O)-NR3-, gde svako R" i R5' je nezavisno vodonik ili C1-6 niži alkil; idalje gde pomenuti alkil su po izboru supstituisani sa jednim, dva, ili tri supstituenta nezavisno odabranih od hidroksila, halo, -NO2, -O-CF3, -O-CHF2, fenila, heterociklila, heteroarila, cikloalkila, -N(R2O)(R22), -C(O)-R20, -C(O)-O-R20, -C(O)-N(R20)(R22), -CN, i -O- R2o ,iligde Ra je odabran iz grupe koja se sastoji odR20 i R22 su u svakom slučaju nezavisno odabrani iz grupe koja se sastoji od vodonika, C1-C15 alkila, C2-C15 alkenila, C2-C15 alkinila, cikloalkila, heterociklila, arila, i heteroarila,gde alkil, alkenil, alkinil, heterociklil, aril, i heteroaril su po izboru supstituisani sa jednim, dva, ili tri supstituenta nezavisno odabranih od hidroksila, halo, alkila, mono- ili dialkilamino, alkil ili aril ili heteroaril amida, -NO2, -SO2R26, -CN, C1-3 alkoksi, -CF3, -OCF3, arila, cikloalkila, i heteroarila; ili;kada R20 i R22 su vezani za zajednički atom azota R20 i R22 se mogu spojiti da formiraju heterociklični prsten koji je zatim po izboru supstituisan sa jedan, dva, ili tri supstituenta nezavisno odabranih od hidroksila, halo, alkila, mono- ili dialkilamino, alkil ili aril ili heteroaril amida, -NO2, -SO2R26, -CN, C1-3 alkoksi, -CF3, i -OCF3, arila, i cikloalkila;R23 je kovalentna veza ili je odabrana iz grupe koja se sastoji od cikloalkilena, heterociklilena, arilena, i heteroarilena,gde cikloalkilen, heterociklilen, arilen, i heteroarilen su po izboru supstituisani sa jednim do tri supstituenta nezavisno odabranih od hidroksila, halo, alkil.a, mono- ili dialkilamino, alkil ili aril ili heteroaril amida, -NO2, -SO2R26, -CN, C1-3 alkoksi, - CF3, -OCF3, arila, cikloalkila, i heteroarila;R24 je u svakom slučaju nezavisno odabran od alkila i l i arila od kojih svaki može po izboru biti supstituisan sa 1, 2, ili 3 grupe nezavisno odabrane od hidroksi la, -OCF3, halo, C1-C3 alkoksi, -O-R20, ili alkila po izboru supstituisanog sa halo, -NO2, -CF3, -O-CF3, -N(R20)(R22), -C(O)-R20, -C(O)-O-R20, -C(O)-N(R20)(R22), -CN, ili -O-R20 ;R25 je u svakom slučaju nezavisno kovalentna veza ili odabran od C1-C3 alkilena po izboru supstituisanog sa jednom ili dve C1 -C3 alkil grupe; iR26 i R28 su u svakom slučaju nezavisno odabrani od vodonika, alki la, ili cikloalkila, gde alkil i cikloalki l mogu dalje biti supstituisani sa od 1 do 3 supstituenta nezavisno odabranih od hidroksil, halo, C1 -4 alkoksi, -CF3, i -OCF3;ili njegove farmaceutski prihvatljive soli, estra, ili solvata,pod uslovima daa. kada Ra je -Y-Z-R25-R23-R20, Y nije kovalentna veza i Z je -0-, -S-, -C(O)-NR3-, -NR5 -C(O)-, ili NR"-, onda R25 ne može biti veza;b. kada Raje -Y-Z-R 25-R23-R20,Y je kovalentna veza i Z je -O-, -S-, ili NR"-, onda R25 je kovalentna veza i R23 nije cikloalkilen;c. kada Z je -NR 5'-C(O)-, onda Y nije kovalentna veza;d. R23 i R25 ne mogu oba biti kovalentne veze; ie. kada Q je veza, i R1 je heteroaril, onda R1 heteroaril možda neće dalje biti supstituisan sa fenilom; if. kada R2 je supstituisan alkil, onda Ra nije alkil, cikloalkil, ili heterociklil.
2. Jedinjenje patentnog zahteva 1 , gde Q je C2-4 alkinilen.
4. Jedinjenje patentnog zahteva 1, gde R1 je heteroaril.
8. Jedinjenje patentnog zahteva 1 , gde R1 je aril po izboru supstituisan sa halo, hidroksil, metoksi, etoksi, -OCF3, ili amino.
11. Jedinjenje bilo kog od patentnih zahteva l do l O za primenu u metodi za lečenje stanja bolesti kod sisara koje je olakšana tretmanom sa agensom koji je sposoban da smanji kasnu struju natrijuma.
12. Primena jedinjenja bilo kog od patentnih zahteva l do l O za pripremanje farmaceutske kompozicije za lečenje stanja bolesti kod sisara koje je olakšano tretmanom sa agensom koji je sposoban da smanji kasnu struju natrijuma.
13. Jedinjenje patentnog zahteva ll ili primena prema patentnom zahtevu 12, gde stanje bolesti je kardiovaskulama bolest odabrana od jedne ili više od atrijalnih i ventrikulamih aritmija, srčane insuficijencije (uključujući kongestivnu srčanu insuficijenciju, dijastolnu srčanu insuficijenciju, sistolnu srčanu insuficijenciju, akutnu srčanu insuficijenciju), Princmetalove (varijantu) angine, stabilne i nestabilne angine, angine izazvane vežbanjem, kongestivne srčane bolesti, ishemije, rekurentne ishemije, reperfuzione povrede, infarktamiokarda, akutnog koronarnog sindroma, periferne arterijske bolesti, plućne hipertenzije, intermitentne klaudikacije; ili stanje bolesti je dijabetes ili dijabetička periferna neuropatija; ili stanje bolesti rezultira u jednom ili više od neuropatskog bola, epilepsije, napada ili paralize.
14. Farmaceutska kompozicija koja sadrži farmaceutski prihvatljiv ekscipijens i terapijski efikasnu količinujedinjenja bilo kog od patentnih zahteva l do 10 ili farmaceutski prihvaljivu so, estar ili hidrat togjedinjenja.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22886409P | 2009-07-27 | 2009-07-27 | |
| US36003710P | 2010-06-30 | 2010-06-30 | |
| EP10737724.4A EP2464645B1 (en) | 2009-07-27 | 2010-07-26 | Fused heterocyclic compounds as ion channel modulators |
| PCT/US2010/043264 WO2011014462A1 (en) | 2009-07-27 | 2010-07-26 | Fused heterocyclic compounds as ion channel modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02847B true ME02847B (me) | 2018-01-20 |
Family
ID=42751632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-235A ME02847B (me) | 2009-07-27 | 2010-07-26 | Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8952034B2 (me) |
| EP (1) | EP2464645B1 (me) |
| CN (1) | CN102725290B (me) |
| AR (1) | AR077598A1 (me) |
| AU (1) | AU2010276537B2 (me) |
| CA (1) | CA2774715C (me) |
| CY (1) | CY1119584T1 (me) |
| DK (1) | DK2464645T3 (me) |
| EA (1) | EA025824B1 (me) |
| ES (1) | ES2642586T3 (me) |
| HR (1) | HRP20171454T8 (me) |
| HU (1) | HUE034911T2 (me) |
| LT (1) | LT2464645T (me) |
| ME (1) | ME02847B (me) |
| NZ (1) | NZ598942A (me) |
| PL (1) | PL2464645T3 (me) |
| PT (1) | PT2464645T (me) |
| RS (1) | RS56410B1 (me) |
| SI (1) | SI2464645T1 (me) |
| SM (1) | SMT201700456T1 (me) |
| TW (2) | TWI542587B (me) |
| UY (1) | UY32805A (me) |
| WO (1) | WO2011014462A1 (me) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201700456T1 (it) | 2009-07-27 | 2017-11-15 | Gilead Sciences Inc | Composti eterociclici fusi come modulatori dei canali ionici |
| JP5858586B2 (ja) | 2010-07-02 | 2016-02-10 | ギリアード サイエンシーズ， インコーポレイテッド | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
| WO2012065297A1 (en) * | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| TWI577670B (zh) | 2011-05-10 | 2017-04-11 | 基利科學股份有限公司 | 充當離子通道調節劑之稠合雜環化合物 |
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (me) | 2011-07-01 | 2018-04-28 | ||
| EP2755976B1 (en) | 2011-09-15 | 2018-07-18 | Novartis AG | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors |
| CA2849505A1 (en) * | 2011-09-21 | 2013-03-28 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| MX356683B (es) | 2011-09-27 | 2018-06-08 | Genfit | Derivados de triazolpiridazinas 6-sustituidas como agonistas rev-erb. |
| RU2014121983A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств |
| US9630929B2 (en) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| US20150045305A1 (en) | 2012-01-27 | 2015-02-12 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| US8952169B2 (en) | 2012-05-22 | 2015-02-10 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
| CN104797555B (zh) | 2012-07-06 | 2017-12-22 | 基因泰克公司 | N‑取代的苯甲酰胺及其使用方法 |
| HK1213476A1 (zh) * | 2013-03-14 | 2016-07-08 | 基因泰克公司 | 取代的三唑並吡啶及其使用方法 |
| CA2898680A1 (en) | 2013-03-15 | 2014-09-18 | Genentech,Inc. | Substituted benzoxazoles and methods of use thereof |
| EP2818471A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 |
| JO3367B1 (ar) * | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| CA2931732A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| GB201321742D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321745D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| NZ720807A (en) * | 2013-12-20 | 2017-02-24 | Gilead Sciences Inc | Fused heterocyclic compounds as ion channel modulators |
| ES2860298T3 (es) | 2014-01-21 | 2021-10-04 | Janssen Pharmaceutica Nv | Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso |
| AU2015208233B2 (en) | 2014-01-21 | 2019-08-29 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| CA2881544A1 (en) * | 2014-02-13 | 2015-08-13 | Anna Chiu | Solid forms of a late sodium current inhibitor |
| WO2016007534A1 (en) | 2014-07-07 | 2016-01-14 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| PE20180575A1 (es) | 2015-05-22 | 2018-04-04 | Genentech Inc | Benzamidas sustituidas y metodos para utilizarlas |
| GB201511790D0 (en) | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
| MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
| BR112018006189A2 (pt) | 2015-09-28 | 2018-10-09 | Genentech Inc | compostos da fórmula, composição farmacêutica, métodos de tratamento de uma doença, de diminuição do fluxo de íons e de tratamento de prurido em um mamífero, método para tratamento de dores em um mamífero e uso de um composto |
| JP2018535234A (ja) | 2015-11-25 | 2018-11-29 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル遮断薬として有用な置換ベンズアミド |
| CN109071426A (zh) | 2016-03-30 | 2018-12-21 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
| WO2018072602A1 (en) | 2016-10-17 | 2018-04-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| PL3548033T3 (pl) * | 2016-11-28 | 2025-06-02 | Praxis Precision Medicines, Inc. | Związki i sposoby ich stosowania |
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体 |
| US11731966B2 (en) | 2017-04-04 | 2023-08-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| EP3759098A1 (en) | 2018-02-26 | 2021-01-06 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
| US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| CN112423760A (zh) * | 2018-05-30 | 2021-02-26 | 普拉克西斯精密药物股份有限公司 | 离子通道调节剂 |
| EA202092908A1 (ru) * | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| BR112022010186A2 (pt) * | 2019-11-26 | 2022-08-09 | Praxis Prec Medicines Inc | Moduladores de canal iônico |
| PE20221280A1 (es) * | 2019-11-27 | 2022-09-05 | Praxis Prec Medicines Inc | Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos |
| JP2023507610A (ja) * | 2019-12-19 | 2023-02-24 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｃｄ２０６モジュレーター、その使用、および調製方法 |
| JP2025515501A (ja) * | 2022-04-26 | 2025-05-15 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | 神経障害の治療 |
Family Cites Families (165)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL128591C (me) * | 1965-07-02 | |||
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4230705A (en) * | 1976-09-22 | 1980-10-28 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety |
| US4242515A (en) | 1979-03-28 | 1980-12-30 | American Cyanamid Company | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines |
| US4244953A (en) * | 1979-10-24 | 1981-01-13 | American Cyanamid Company | Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4812565A (en) * | 1982-09-30 | 1989-03-14 | A. H. Robins Company, Incorporated | Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof |
| US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4654343A (en) * | 1985-10-31 | 1987-03-31 | American Cyanamid Company | N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4746655A (en) * | 1987-06-10 | 1988-05-24 | A. H. Robins Company, Incorporated | Fused aromatic-spiropiperidine oxazepinones(and thiones) |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) * | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| DE4010488A1 (de) | 1990-03-31 | 1991-10-02 | Hoechst Ag | Benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zum behandeln oder zur prophylaxe von krankheiten |
| CA2044564A1 (en) * | 1990-06-28 | 1991-12-29 | Quirico Branca | Amino acid derivatives |
| CN1060467A (zh) | 1990-09-25 | 1992-04-22 | 武田药品工业株式会社 | 1，3-苯并嗪衍生物、其生产方法和用途 |
| JPH04209692A (ja) | 1990-12-03 | 1992-07-31 | Asahi Glass Co Ltd | フォトクロミック材料 |
| DE69209576D1 (de) | 1991-05-10 | 1996-05-09 | Takeda Chemical Industries Ltd | Pyridinderivate, deren Herstellung und Anwendung |
| US5939412A (en) * | 1992-06-26 | 1999-08-17 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
| DE69232854T2 (de) | 1991-06-28 | 2003-09-04 | Smith-Kline Beecham Corp., King Of Prussia | Bizyklische fibrinogenantagonisten |
| US5250679A (en) | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
| US5663166A (en) * | 1991-10-18 | 1997-09-02 | Genentech, Inc. | Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor |
| US5272158A (en) | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| JPH06107647A (ja) | 1992-08-12 | 1994-04-19 | Takeda Chem Ind Ltd | １，３−ベンゾオキサジン誘導体の製造法 |
| US5442055A (en) | 1992-11-13 | 1995-08-15 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
| US6011150A (en) * | 1992-11-13 | 2000-01-04 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
| GB9225860D0 (en) | 1992-12-11 | 1993-02-03 | Smithkline Beecham Plc | Novel treatment |
| GB9226302D0 (en) | 1992-12-17 | 1993-02-10 | Smithkline Beecham Plc | Pharmaceuticals |
| US5550229A (en) | 1993-06-23 | 1996-08-27 | Tanabe Seiyaku Co., Ltd. | Alkylation process for preparing azetidinone compound and starting compound therefor |
| DE19526173A1 (de) | 1995-07-18 | 1997-01-30 | Hoechst Ag | Polyfullerenaddukte, Verfahren zu ihrer regioselektiven Herstellung und deren Verwendung |
| JPH09157262A (ja) | 1995-12-08 | 1997-06-17 | Tanabe Seiyaku Co Ltd | アゼチジノン誘導体及びその合成中間体の製法 |
| GB9619492D0 (en) | 1996-09-18 | 1996-10-30 | Smithkline Beecham Plc | Novel treatment |
| EP0975614A1 (en) | 1997-04-18 | 2000-02-02 | Smithkline Beecham Plc | A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity |
| JP3964053B2 (ja) | 1997-07-10 | 2007-08-22 | 三井化学株式会社 | 遷移金属化合物からなるオレフィン重合用触媒ならびに重合方法 |
| TR200000624T2 (tr) | 1997-09-08 | 2000-11-21 | Unilever N.V. | Bir enzimin etkinliğinin arttırılması ile ilgili bir yöntem. |
| US6579875B1 (en) * | 1998-01-21 | 2003-06-17 | Merck Sharp & Dohme Limited | Triazolo-pyridazine derivatives as ligands for GABA receptors |
| EP1054877A1 (en) | 1998-02-11 | 2000-11-29 | Du Pont Pharmaceuticals Company | Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors |
| ZA991301B (en) | 1998-02-18 | 1999-09-13 | Neurosearch As | Glutamate receptor modulators. |
| US6479506B1 (en) * | 1998-06-16 | 2002-11-12 | Merck Sharp & Dohme Ltd. | Triazolo-pyridine derivatives as ligands for GABA receptors |
| AU6325799A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
| EP1182195A4 (en) | 1999-05-07 | 2003-03-26 | Takeda Chemical Industries Ltd | CYCLIC CONNECTIONS AND APPLICATIONS THEREOF |
| AU6935500A (en) | 1999-08-27 | 2001-03-26 | Procter & Gamble Company, The | Stability enhancing formulation components, compositions and laundry methods employing same |
| BR0013610A (pt) | 1999-08-27 | 2002-07-16 | Procter & Gamble | Componentes de formulções de ação rápida,composições e métodos para lavar roupa empregando os mesmos |
| CA2381892A1 (en) | 1999-08-27 | 2001-03-08 | The Procter & Gamble Company | Bleach boosting components, compositions and laundry methods |
| WO2001016274A1 (en) | 1999-08-27 | 2001-03-08 | The Procter & Gamble Company | Stable formulation components, compositions and laundry methods employing same |
| BR0013647A (pt) | 1999-08-27 | 2002-05-07 | Procter & Gamble | Métodos de lavagem com proteção á cor empregando componentes de formulação catiÈnicas |
| CA2381924A1 (en) | 1999-08-27 | 2001-03-08 | The Procter & Gamble Company | Color safe laundry methods employing zwitterionic formulation components |
| TR200201062T2 (tr) | 1999-08-27 | 2003-02-21 | The Procter & Gamble Company | Formülasyon bileşenlerinin denetimli kullanılabilirliği ve bundan yararlanılan bileşimler. |
| EP1286994A1 (en) | 2000-05-15 | 2003-03-05 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| CZ2003284A3 (cs) | 2000-08-01 | 2003-09-17 | Ono Pharmaceutical Co., Ltd. | 3,4-Dihydroisochinolinový derivát a farmaceutické činidlo obsahující tento derivát jako účinnou složku |
| US20040058915A1 (en) | 2000-08-29 | 2004-03-25 | Khanna Ish Kumar | Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists |
| JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
| DE60123665T2 (de) | 2000-12-26 | 2007-08-16 | Sankyo Co., Ltd. | Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel |
| KR20030080087A (ko) | 2001-03-09 | 2003-10-10 | 화이자 프로덕츠 인코포레이티드 | 항염증제로서의 트리아졸로피리딘 |
| US6998408B2 (en) * | 2001-03-23 | 2006-02-14 | Bristol-Myers Squibb Pharma Company | 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors |
| US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| JP2005089298A (ja) | 2001-09-18 | 2005-04-07 | Japan Tobacco Inc | ナフタレン化合物及びその医薬用途 |
| US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| JP2003277384A (ja) | 2002-03-26 | 2003-10-02 | Kyorin Pharmaceut Co Ltd | 縮合ニ環式ピリジン誘導体 |
| JP2003321461A (ja) | 2002-04-25 | 2003-11-11 | Kyorin Pharmaceut Co Ltd | 縮合ビフェニル誘導体 |
| CA2497658A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
| PA8579601A1 (es) * | 2002-08-30 | 2004-05-07 | Pfizer Prod Inc | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas |
| US7005523B2 (en) * | 2002-08-30 | 2006-02-28 | Pfizer Inc. | Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines |
| AU2003262073A1 (en) | 2002-09-20 | 2004-04-08 | Tsumura And Co. | Antitussives |
| US20040204404A1 (en) * | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
| WO2004037997A2 (en) | 2002-10-22 | 2004-05-06 | The Trustees Of The University Of Pennsylvania | Fragments and activity of rel protein in m. tuberculosis adn other uses thereof |
| EP1562925B1 (en) * | 2002-11-07 | 2007-01-03 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| WO2004062616A2 (en) | 2003-01-13 | 2004-07-29 | Cortex Pharmaceuticals, Inc. | Method of treating cognitive decline due to sleep deprivation and stress |
| AR044503A1 (es) | 2003-03-18 | 2005-09-14 | Merck & Co Inc | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio |
| DE10317526A1 (de) | 2003-04-16 | 2004-11-04 | Degussa Ag | Verfahren zum Delignifizieren von ligninhaltigen Faserstoffen |
| AU2004232939A1 (en) | 2003-04-17 | 2004-11-04 | Merck Sharp & Dohme Corp. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
| WO2004096767A1 (en) | 2003-04-25 | 2004-11-11 | H. Lundbeck A/S | Sustituted indoline and indole derivatives |
| JP2007521296A (ja) | 2003-07-01 | 2007-08-02 | メルク エンド カムパニー インコーポレーテッド | 高眼圧の治療のための眼科用組成物 |
| EP1663994B1 (en) * | 2003-08-05 | 2012-03-07 | Vertex Pharmaceuticals Incorporated | Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels |
| US20050239767A1 (en) * | 2003-10-28 | 2005-10-27 | Chan Michael K | Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands |
| CN1893950A (zh) | 2003-12-18 | 2007-01-10 | 辉瑞产品公司 | 用p38 MAP激酶抑制剂治疗动物急性炎症的方法 |
| US7306631B2 (en) * | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| GB0412986D0 (en) * | 2004-06-10 | 2004-07-14 | Xention Discovery Ltd | Compounds |
| WO2006002470A1 (en) | 2004-06-30 | 2006-01-12 | Monash University | Chiral ligands for asymmetric catalysis |
| JP2006063064A (ja) | 2004-07-27 | 2006-03-09 | Takeda Chem Ind Ltd | 受容体作動剤 |
| JP2007297283A (ja) | 2004-07-28 | 2007-11-15 | Santen Pharmaceut Co Ltd | 新規桂皮酸関連化合物 |
| CA2577060A1 (en) | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| CA2576465A1 (en) | 2004-08-23 | 2006-03-02 | Merck & Co., Inc. | Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| CN101076527B (zh) | 2004-09-13 | 2011-11-30 | 默沙东公司 | 三环酰苯胺螺乙内酰脲cgrp受体拮抗剂 |
| WO2006048727A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Products Inc. | Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor |
| US7579348B2 (en) * | 2005-02-25 | 2009-08-25 | Pgxhealth, Llc | Derivatives of 8-substituted xanthines |
| TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
| AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| EP2444079B1 (en) | 2005-05-17 | 2016-11-30 | SARcode Bioscience Inc. | Compositions and Methods for Treatment of Eye Disorders |
| TW200714597A (en) | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| US7572807B2 (en) * | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US7495111B2 (en) | 2005-06-17 | 2009-02-24 | Wyeth | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists |
| US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| US7572808B2 (en) | 2005-06-17 | 2009-08-11 | Bristol-Myers Squibb Company | Triazolopyridine cannabinoid receptor 1 antagonists |
| WO2007004028A2 (en) | 2005-06-30 | 2007-01-11 | Ranbaxy Laboratories Limited | Processes for the preparation of penems and its intermediate |
| GB0516963D0 (en) * | 2005-08-18 | 2005-09-28 | Carbonite Corp | Liquid dispensers |
| WO2007023750A1 (ja) | 2005-08-26 | 2007-03-01 | National University Corporation University Of Toyama | 乾燥羊膜及び羊膜の乾燥処理方法 |
| CA2621255A1 (en) * | 2005-09-21 | 2007-04-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| CA2623026A1 (en) | 2005-09-23 | 2007-04-05 | Schering Corporation | Fused tetracyclic mglur1 antagonists as therapeutic agents |
| US20090022694A1 (en) | 2005-10-18 | 2009-01-22 | Distefano Peter | Sirt1 inhibition |
| TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
| EP1954135B1 (en) | 2005-11-18 | 2012-10-10 | Merck Sharp & Dohme Corp. | Spirolactam aryl cgrp receptor antagonists |
| US8071772B2 (en) | 2005-11-18 | 2011-12-06 | Merck Sharp & Dohme Corp. | Spirolactam bicyclic CGRP receptor antagonists |
| TW200734342A (en) | 2005-12-15 | 2007-09-16 | Astrazeneca Ab | New compounds for the treatment of cardiac arrhythmias |
| WO2007070866A2 (en) | 2005-12-16 | 2007-06-21 | Alcon, Inc. | Control of intraocular pressure using alk5 modulation agents |
| US8013073B2 (en) | 2005-12-30 | 2011-09-06 | Chevron Oronite Company Llc | Method for preparing polyolefins containing vinylidine end groups using nonaromatic heterocyclic compounds |
| WO2007113226A1 (en) * | 2006-03-31 | 2007-10-11 | Novartis Ag | Organic compounds |
| JP2009539988A (ja) | 2006-06-12 | 2009-11-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルの調節因子として有用なチエノピリミジン |
| EP2035372A1 (en) | 2006-06-29 | 2009-03-18 | Arena Pharmaceuticals, Inc. | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
| EP2038272B8 (en) | 2006-06-30 | 2013-10-23 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl pdk1 inhibitors |
| WO2008007661A1 (en) | 2006-07-11 | 2008-01-17 | Takeda Pharmaceutical Company Limited | Tricyclic heterocyclic compound and use thereof |
| WO2008006540A1 (en) * | 2006-07-12 | 2008-01-17 | Syngenta Participations Ag | Triazolopyridine derivatives as herbicides |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (es) * | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| WO2008063287A2 (en) * | 2006-10-06 | 2008-05-29 | Abbott Laboratories | Novel imidazothiazoles and imidazoxazoles |
| WO2008118141A2 (en) | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| AU2007309427B2 (en) * | 2006-10-23 | 2013-02-28 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors |
| CN103275067B (zh) | 2006-10-28 | 2015-09-02 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| EP2128134A1 (en) * | 2006-11-02 | 2009-12-02 | Shionogi&Co., Ltd. | Sulfonylurea derivative capable of selectively inhibiting mmp-13 |
| EP2101775A1 (en) | 2006-12-21 | 2009-09-23 | Cv Therapeutics, Inc. | Reduction of cardiovascular symptoms |
| US8076350B2 (en) | 2006-12-22 | 2011-12-13 | Abbott Laboratories | Spirocyclic azaadamantane derivatives and methods of use |
| AR065081A1 (es) | 2007-01-29 | 2009-05-13 | Xenon Pharmaceuticals Inc | Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica |
| JP2010520237A (ja) * | 2007-02-28 | 2010-06-10 | メルク・シャープ・エンド・ドーム・コーポレイション | ナトリウムチャネル遮断薬としての置換ベンゾジアゼピノン、ベンゾオキサアゼピノン及びベンゾチアゼピノン |
| EP2123644B1 (en) | 2007-03-07 | 2014-12-17 | Takeda Pharmaceutical Company Limited | Benzoxazepine derivatives and use thereof |
| GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| WO2008134553A1 (en) | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using bicyclic compounds in treating sodium channel-mediated diseases |
| WO2008144483A2 (en) | 2007-05-18 | 2008-11-27 | Armgo Pharma, Inc. | Agents for treating disorders involving modulation of ryanodine receptors |
| EP2170337A4 (en) * | 2007-06-28 | 2013-12-18 | Abbvie Inc | NEW TRIAZOLOPYRIDAZINE |
| WO2009026444A1 (en) | 2007-08-22 | 2009-02-26 | President And Fellows Of Harvard College | Ryanodine channel binders and uses thereof |
| EA201000316A1 (ru) * | 2007-09-12 | 2010-10-29 | ВАЙЕТ ЭлЭлСи | Производные изохинолинила и изоиндолинила в качестве антагонистов гистаминовых рецепторов 3 подтипа |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| NZ585306A (en) | 2007-12-19 | 2012-05-25 | Genentech Inc | 8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
| WO2009089027A1 (en) | 2008-01-09 | 2009-07-16 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service, National Institutes Of Health | Phosphodiesterase inhibitors |
| EA201070914A1 (ru) * | 2008-02-06 | 2011-04-29 | Гайлид Сайэнсиз, Инк. | Применение ранолазина для лечения боли |
| WO2009137499A1 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Inhibitors of histone deacetylase |
| WO2009137462A2 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| DE102008024182A1 (de) | 2008-05-19 | 2009-11-26 | Merck Patent Gmbh | Verbindungen für organische elektronische Vorrichtung |
| MX2010014057A (es) | 2008-06-17 | 2011-03-21 | Astrazeneca Ab | Compuestos de piridina. |
| WO2010006292A1 (en) | 2008-07-11 | 2010-01-14 | Neumedics | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits |
| KR101315628B1 (ko) | 2008-08-12 | 2013-10-08 | 닛뽕소다 가부시키가이샤 | 함질소 헤테로고리 유도체 및 농원예용 살균제 |
| WO2010022001A1 (en) | 2008-08-18 | 2010-02-25 | Im&T Research, Inc. | Methods for preparing fluoroalkyl arylsulfinyl compounds and fluorinated compounds thereto |
| CA2735653A1 (en) * | 2008-09-04 | 2010-03-11 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
| WO2010053757A1 (en) * | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| US8389500B2 (en) * | 2008-10-30 | 2013-03-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| CN102307871A (zh) | 2008-12-08 | 2012-01-04 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的异吲哚啉酮和相关的类似物 |
| WO2010077680A2 (en) | 2008-12-08 | 2010-07-08 | Vm Discovery Inc. | Compositions of protein receptor tyrosine kinase inhibitors |
| FR2943342B1 (fr) * | 2009-03-20 | 2011-03-04 | Servier Lab | Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| CA2755658A1 (en) | 2009-03-27 | 2010-09-30 | Presidio Pharmaceuticals, Inc. | Fused ring inhibitors of hepatitis c |
| WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| SMT201700456T1 (it) | 2009-07-27 | 2017-11-15 | Gilead Sciences Inc | Composti eterociclici fusi come modulatori dei canali ionici |
| WO2011036280A1 (en) * | 2009-09-28 | 2011-03-31 | F. Hoffmann-La Roche Ag | Benzoxazepin pi3k inhibitor compounds and methods of use |
| WO2011075607A1 (en) | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| TWI508726B (zh) * | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
| JP5858586B2 (ja) * | 2010-07-02 | 2016-02-10 | ギリアード サイエンシーズ， インコーポレイテッド | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
| WO2012019071A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating sarcopenia |
| WO2012019076A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury |
| WO2012037105A1 (en) | 2010-09-14 | 2012-03-22 | The Trustees Of Columbia University In The City Of New York | Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases |
| WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
| WO2012071509A2 (en) | 2010-11-24 | 2012-05-31 | Exelixis, Inc. | Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture |
| TWI577670B (zh) * | 2011-05-10 | 2017-04-11 | 基利科學股份有限公司 | 充當離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (me) * | 2011-07-01 | 2018-04-28 | ||
| TWI478908B (zh) * | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| US20150045305A1 (en) | 2012-01-27 | 2015-02-12 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
-
2010
- 2010-07-26 SM SM20170456T patent/SMT201700456T1/it unknown
- 2010-07-26 ES ES10737724.4T patent/ES2642586T3/es active Active
- 2010-07-26 HU HUE10737724A patent/HUE034911T2/hu unknown
- 2010-07-26 WO PCT/US2010/043264 patent/WO2011014462A1/en not_active Ceased
- 2010-07-26 LT LTEP10737724.4T patent/LT2464645T/lt unknown
- 2010-07-26 CA CA2774715A patent/CA2774715C/en active Active
- 2010-07-26 EP EP10737724.4A patent/EP2464645B1/en active Active
- 2010-07-26 HR HRP20171454TT patent/HRP20171454T8/hr unknown
- 2010-07-26 RS RS20170990A patent/RS56410B1/sr unknown
- 2010-07-26 SI SI201031540T patent/SI2464645T1/sl unknown
- 2010-07-26 PL PL10737724T patent/PL2464645T3/pl unknown
- 2010-07-26 EA EA201290121A patent/EA025824B1/ru unknown
- 2010-07-26 US US12/843,702 patent/US8952034B2/en active Active
- 2010-07-26 DK DK10737724.4T patent/DK2464645T3/en active
- 2010-07-26 PT PT107377244T patent/PT2464645T/pt unknown
- 2010-07-26 AU AU2010276537A patent/AU2010276537B2/en active Active
- 2010-07-26 NZ NZ598942A patent/NZ598942A/en active Application Filing
- 2010-07-26 CN CN201080043104.0A patent/CN102725290B/zh active Active
- 2010-07-26 ME MEP-2017-235A patent/ME02847B/me unknown
- 2010-07-27 AR ARP100102716A patent/AR077598A1/es not_active Application Discontinuation
- 2010-07-27 TW TW104112388A patent/TWI542587B/zh active
- 2010-07-27 TW TW099124710A patent/TWI490217B/zh active
- 2010-07-27 UY UY0001032805A patent/UY32805A/es not_active Application Discontinuation
-
2014
- 2014-05-09 US US14/274,422 patent/US9371329B2/en active Active
-
2017
- 2017-10-04 CY CY20171101028T patent/CY1119584T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02847B (me) | Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala | |
| JP2008523069A5 (me) | ||
| SI2966067T1 (en) | OKSAZEPINI AS ION CHANNEL MODULATORS | |
| JP2006143746A5 (me) | ||
| CA2679232A1 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof | |
| ME01294B (me) | Nova jedinjenja i kompozicije i metode upotrebe | |
| RU2010133903A (ru) | Способ и промежуточные соединения для получения производных 5-бифенил-4-ил-2-метилпентановой кислоты | |
| JP2009527501A5 (me) | ||
| JP2010529033A5 (me) | ||
| JP2010540477A5 (me) | ||
| JP2010510232A5 (me) | ||
| CN108675937A (zh) | 一种α-氨基酸的合成方法 | |
| RU2010147865A (ru) | Производные бензимидазола | |
| SU906346A3 (ru) | Фунгицидное средство | |
| CN100579970C (zh) | 杀菌剂异噻唑啉酮的制备方法 | |
| DK1474426T3 (da) | Fremgangsmåde til fremstilling af carbapenemforbindelser | |
| JP2011500796A (ja) | 新規前駆体 | |
| JP2006517932A5 (me) | ||
| ES2923932T3 (es) | Un procedimiento mejorado para la preparación de rivaroxabán que implica un intermedio novedoso | |
| ES2547697T3 (es) | Atropisómeros de (hidroxialquil)pirrol derivados | |
| FI59802B (fi) | Foerfarande foer framstaellning av farmakologiskt vaerdefulla nya substituerade 2-fenylamino-imidazoliner-(2) och deras syraadditionssalter | |
| RU2008128566A (ru) | Органические соединения | |
| JP2013536823A5 (me) | ||
| JP2007532700A5 (me) | ||
| FI71738B (fi) | Foerfarande foer framstaellning av 5,6,7,7a-tetrahydro-4h-tien(3,2-c)pyridin-2-onderivat |